Synthesis and in vitro characterization of superparamagnetic γ-Fe2O3-containing 13–93 bioactive glasses for bone cancer therapy. Issue 23 (1st December 2022)

• Record Type: Journal Article
• Authors: Saatci, Mehmet; Deliormanlı, Aylin M.; Atmaca, Harika
• Is Part Of: Ceramics international. Volume 48:Issue 23(2022)Part A
• Page Start: 34382
• Page End: 34394
• Publication Date: 2022-12-01
• Subjects: Superparamagnetic -- Bioactive glass -- Maghemite -- Bone cancer; Ceramics -- Periodicals; Céramique industrielle -- Périodiques; Ceramics; Periodicals; Electronic journals; 666
• DOI: 10.1016/j.ceramint.2022.08.017
• Languages: English
• ISSNs: 0272-8842

Abstract

Abstract: Osteosarcoma is one of the most common types of bone cancer, which generally starts in the long bones. In this study, superparamagnetic maghemite-containing (2, 5, 10, 20 wt%) bioactive glass powders were prepared for the treatment of osteosarcoma. For this purpose, maghemite nanoparticles were synthesized using the co-precipitation technique, and maghemite-containing bioactive glass-ceramic composites were fabricated through the sol-gel process. The structural, morphological, thermal, and magnetic properties and the in vitro bioactivity of the prepared bioactive glasses were investigated. In vitro cytotoxicity was examined using SaOS-2 and MC3T3-E1 cells. The fluorouracil (5-FU) release behavior of the studied bioactive glass powders was also monitored in phosphate-buffered saline as a function of time. Results revealed that synthesized maghemite nanoparticles as well as the maghemite-containing bioactive glass-ceramic composites have superparamagnetic properties. They have high bioactivity, with up to 5 wt% maghemite content. Prepared bioactive glass composites have no cytotoxicity against osteosarcoma and pre-osteoblast cells at low concentrations. Drug-loaded bioactive glass powder showed sustained release behavior. Overall results indicated that prepared glass composites have a high potential to be used in magnetic hyperthermia and anticancer drug release applications for the treatment of bone cancer.